Fig. 2From: Feasibility study of docetaxel plus bevacizumab as first line therapy for elderly patients with advanced non-small-cell lung cancer: Thoracic Oncology Research Group (TORG) 1014Waterfall plot of best percent change in target lesions in each cohort. BV, bevacizumab; DTX, docetaxelBack to article page